Technology

DelAQUA Platform

Robust and Tunable block copolymer platform enables delivery of highly loaded micelles with one, two, and even three API in a single micelle. Improves safety and toxicity profile of API.

DelAQUA’s “POxol” High-Dose Paclitaxel Formulation is Bioequivalent to Abraxane

POxol High Dose Paclitaxel Performs Comparable to Abraxane® in mouse models of Breast Cancer

DelAQUA’s POxol High Dose Paclitaxel performs comparably to Abraxane® across mouse models of breast cancer

POxol High Dose Paclitaxel demonstrates reduced toxicity and higher tolerated dose compared to Abraxane®

POxol High Dose Paclitaxel meets FDA definition of Bioequivalence to Abraxane® in Rats and Non-Human Primates

Excipient enables formulation of drugs for 505(b)2 regulatory approval pathway

POxol High Dose Paclitaxel (PTX) Demonstrates Bioequivalence in Rats and Non-Human Primates

DelAQUA Solves the BBB: Increased drug delivery to the brain with POx Copolymers Palbociclib and BT44 Case Studies

POx micelles deliver more Palbociclib in Medulloblastoma Model

Accumulation of Palbociclib in serum, forebrain and tumor was higher for POx micelles than free drug (IP injection)

POx-Palbo had ~1.5x higher Cmax in forebrain and tumor

Palbo-POx had 1.8x and 2.3x higher AUC in forebrain and tumor, respectively, and 2X serum exposure

Lim et al, Sci Adv. 8, eabl5838 (2022)

POx micelles deliver more BT44 to brain via SC injection

POx micelles deliver 12x more BT44 to brain via subcutaneous injection than PG solubilized drug

The relative increase of BT44 concentration using POx-BT44 vs PG-BT44 was approximately two times higher in brain (b) than in plasma (a)

POx-BT44 was remarkably safer than PG-BT44 formulation as measured by behavioral parameters

Haider et al., Biomacromolecules 2023, 24, 4348

DelAQUA’s Poly(2-Oxazoline) Platform Enables Co-Delivery of Multiple API to Target Site for Synergistic Effects and Improved Therapeutic Outcomes

Del Aqua’s High Dose Paclitaxel (PTX) Co-Loaded with Immunomodulating CSF1R Inhibitor (PLX)

Co-Loading enables the delivery of synergistic combinations at the desired ratios to the site of disease

DelAQUA’s Poly(2-Oxazoline) platform allows unparalleled co-delivery in the nanomedicines space

DelAQUA’s Poly(2-Oxazoline) platform allows unparalleled co-delivery in the nanomedicines space

Del AQUA’s Dual-Chemotherapy Enabling Micelles, Paclitaxel and Cisplatin Pro-Drug

Combination Loaded micelles improve the delivery (C-max and AUC) to tumors of both API

Combination Loaded micelles (Red) outperform single drug and non-coloaded micelles (Blue)

Co-loading improves micelle stability in vivo, slowing release, and increasing delivery efficiency

DelAQUA Polymers improve Oral Bioavailability of both P-gp substrate and non-substrate API with patented Poly(2-Oxazoline) technology

Improved Bioavailability of Non-Pgp Substrates (Collaboration with Boehringer-Ingelheim)

In collaborative study with Boehringer-Ingelheim (Germany), POx polymers improved poorly soluble API oral bioavailability by 6-fold in Rats

Achieved near quantitative drug exposure through nanosuspension

Opportunities for easy to swallow suspension and capsules for pediatric and geriatric products

DelAQUA Enables Oral Paclitaxel (PTX) Delivery

DLQ+ Technology enables unrivaled 76.9%Paclitaxel Oral Bioavailability

Enables low-dose daily administration of critical oncology drug

Formulation stable for months as solution or lyophilized powder

DelAQUA Polymers are near ubiquitous stabilizers of drug nanocrystal suspensions

Bottom Up Preparation Enables Inhalation Delivery of Remdesivir

Increases API solubility in suspension up to 10,000-fold

Low foaming of excipients yield consistent output of fine particles from nebulizer over dosing period

Output is comparable to other nanocrystal inhalable formulations on the market

Top-Down Milling improves Dissolution Profile, Reducing Toxicity

DelAQUA Milled Nanocrystals (red) improve dissolution profile, reducing C-max and mitigating toxicity

Formulations easily stored frozen and readily scalable for large batches

Comparable AUC achieved with very low intersubject variability

DelAQUA’s Versatile Polymer Platform Enables Delivery and Improves Efficacy

DelAQUA’s High Dose Paclitaxel performs comparably to Abraxane® across mouse models and meets FDA Bioequivalence definition

DelAQUA’s platform allows for the co-encapsulation and delivery of up to four API in the same micelle for synergistic effect

POx platform overcomes classic barriers to drug delivery in the BBB and GI tract

Increases solubility of poorly soluble API up to 100,000-fold! Platform compatible with at least 80% of tested API

Enables dosing solution for intravenous, oral, inhalation, intraperitoneal, nasal, ocular, topical, and subcutaneous administration

Polymeric micelles and nanocrystals enable enhanced delivery to multiple sites of disease

PHARMACEUTICALS

Technology

DelAQUA Platform

DelAQUA’s “POxol” High-Dose Paclitaxel Formulation is Bioequivalent to Abraxane

DelAQUA Solves the BBB: Increased drug delivery to the brain with POx Copolymers Palbociclib and BT44 Case Studies

DelAQUA’s Poly(2-Oxazoline) Platform Enables Co-Delivery of Multiple API to Target Site for Synergistic Effects and Improved Therapeutic Outcomes

DelAQUA Polymers improve Oral Bioavailability of both P-gp substrate and non-substrate API with patented Poly(2-Oxazoline) technology

DelAQUA Polymers are near ubiquitous stabilizers of drug nanocrystal suspensions

PHARMACEUTICALS

PHARMACEUTICALS

Technology

DelAQUA Platform

​

DelAQUA Solves the BBB: Increased drug delivery to the brain with POx Copolymers Palbociclib and BT44 Case Studies

PHARMACEUTICALS